Recent Updates
Recently added Catalysts
OSUR Positive Sentiment Score: 70/100

OraSure to Participate in Upcoming Investor Conference

Key Takeaway: OraSure Technologies, Inc. (NASDAQ: OSUR) has announced its participation in the upcoming Stephens Annual Investment Conference on November 19, which includes a Q&A session at 10 a.m. CT. The company will provide a live webcast and replay of the session on their investor relations website. OraSure focuses on decentralizing diagnostics, innovating in health technology, and improving access to healthcare through various products. This initiative indicates their commitment to maintaining transparent communication with shareholders and the market.

Market Sentiment Analysis

POSITIVE FACTORS

  • OraSure is actively engaging with investors, showcasing their business strategy.
  • Participation in the prestigious Stephens Annual Investment Conference highlights credibility.
  • The company continues to innovate in diagnostics, suggesting growth potential.

Full Press Release Details

BETHLEHEM, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) announced today that the company is scheduled to participate in the following investor conference:
Stephens Annual Investment Conference on Wednesday, November 19, with a Q&A session scheduled for 10 a.m. CT
A live webcast and replay of the Q&A session will be available on the investor relations page of OraSure’s website at https://orasure.gcs-web.com/events-and-presentations.
About OraSure Technologies, Inc.
OraSure Technologies, Inc. (“OraSure” and “OTI”) transforms health through actionable insight and decentralizes diagnostics to connect people to healthcare wherever they are. OTI improves access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. Together with its wholly-owned subsidiaries, DNA Genotek Inc. and Sherlock Biosciences, Inc., OTI is a leader in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. OTI’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct to consumers. For more information, please visit www.orasure.com
Investor Contact: Media Contact:
Jason Plagman Amy Koch
VP, Investor Relations Director, Corporate Communications
investorinfo@orasure.com media@orasure.com

Frequently Asked Questions

When is the Stephens Annual Investment Conference scheduled?

The Stephens Annual Investment Conference is on November 19 at 10 a.m. CT.

Where can I watch the Q&A session online?

The Q&A session will be live-streamed on OraSure’s investor relations page.

What does OraSure Technologies, Inc. specialize in?

OraSure specializes in diagnostics and sample management solutions for healthcare.

Who are OraSure's main subsidiaries?

OraSure’s main subsidiaries are DNA Genotek Inc. and Sherlock Biosciences, Inc.

What types of products does OraSure produce?

OraSure produces rapid diagnostic tests and sample collection devices.

Last updated: Nov 17, 2025